Neoadjuvant anti-CTLA4 and anti-PD1 blockade in advanced urothelial cancer

被引：1
|
作者：
Tregunna R.
机构：
[1] Nature Reviews Urology,
来源：
Nature Reviews Urology | 2020年 / 17卷 / 12期
关键词：
D O I：
10.1038/s41585-020-00399-0
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
下载
收藏
页码：658 / 658
相关论文
共 50 条
  • [1] Response assessment to anti-CTLA4 or/and anti-PD1 immunotherapy in mucosal melanomas
    Moya-Plana, Antoine
    Herrera-Gomez, Ruth Gabriela
    Rossoni, Caroline
    Dercle, Laurent
    Ammari, Samy
    Girault, Isabelle
    Roy, Severine
    Scoazec, Jean-Yves
    Vagner, Stephan
    Janot, Francois
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Enhancement of anti-PD1 and anti-CTLA4 efficacy by NBTXR3 nanoparticles exposed to radiotherapy
    Hu, Yun
    Zhang, Ping
    Darmon, Audrey
    Cortez, Maria Angelica
    Paris, Sebastien
    Welsh, James
    CANCER RESEARCH, 2019, 79 (13)
  • [3] Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo
    Das, Rituparna
    Verma, Rakesh
    Sznol, Mario
    Boddupalli, Chadra Sekhar
    Gettinger, Scott
    Kluger, Harriet
    Dhodapkar, Madhav
    Dhodapkar, Kavita
    CANCER RESEARCH, 2015, 75
  • [4] The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China A bibliometrics study
    Zhao, Xiaoqin
    He, Liangmei
    Mao, Kaiyun
    Chen, Daming
    Jiang, Hongbo
    Liu, Zhiping
    MEDICINE, 2018, 97 (15)
  • [5] Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy
    Lee, J. H.
    Lim, S. Y.
    Menzies, A. M.
    Carlino, M. S.
    Guminski, A.
    Nahar, K.
    Palmieri, D.
    Breen, E.
    Kefford, R.
    Scolyer, R.
    Long, G. V.
    Rizos, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 659 - 659
  • [6] Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy
    Godse, R.
    Mcgettigan, S.
    Schuchter, L. M.
    Ellebrecht, C. T.
    Chu, E. Y.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (06) : 1111 - +
  • [7] NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
    Hu, Yun
    Paris, Sebastien
    Bertolet, Genevieve
    Barsoumian, Hampartsoum B. B.
    Wang, Qi
    Da Silva, Jordan
    Patel, Nalini B. B.
    Nguyen, Nguyen
    Doss, Denaha J. J.
    Huang, Ailing
    Hsu, Ethan
    Leyton, Claudia S. Kettlun
    Voss, Tiffany A. A.
    Masrorpour, Fatemeh
    Leuschner, Carola
    Pietz, Jordan T. T.
    Puebla-Osorio, Nahum
    Gandhi, Saumil
    Nguyen, Quynh-Nhu
    Wang, Jing
    Cortez, Maria Angelica
    Welsh, James W. W.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma
    Aya Moreno, F.
    Fernandez-Martinez, A.
    Gaba, L.
    Victoria, I.
    Arance Fernandez, A. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 6 - 6
  • [9] Regulatory T-cells and effects of anti-CTLA4 and anti-PD1 therapy in a transgenic murine model of neuroblastoma
    Chan, Randall
    Shirinbak, Soheila
    Muthugounder, Sakunthala
    Hung, Long
    Gnanachandran, Janahan
    Hajidaniel, Michael
    Asgharzadeh, Shahab
    CANCER RESEARCH, 2014, 74 (19)
  • [10] In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies
    Sanvicente, Adrian
    Diaz-Tejeiro, Cristina
    Nieto-Jimenez, Cristina
    Paniagua-Herranz, Lucia
    Cade, Igor Lopez
    Balazs, Gyorffy
    Moreno, Victor
    Perez-Segura, Pedro
    Calvo, Emiliano
    Ocana, Alberto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
12345